| Dr Shane Taylor Wilkinson, DC | |
|
1607 Johnson St., Jennings, LA 70546 | |
| (337) 824-5522 | |
| (337) 824-5527 |
| Full Name | Dr Shane Taylor Wilkinson |
|---|---|
| Gender | Male |
| Speciality | Chiropractor |
| Location | 1607 Johnson St., Jennings, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124248968 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 1735 (Louisiana) | Primary |
| Provider Name | Chiropractic America,llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1063518454 PECOS PAC ID: 4688577216 Enrollment ID: O20040130000080 |
News Archive
MicroStockProfit.com announces an investment report featuring Virtual Radiologic Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.
Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
› Verified 1 days ago
| Provider Name | Joseph A. Livergood, Dc, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760997241 PECOS PAC ID: 4486985512 Enrollment ID: O20191003002610 |
News Archive
MicroStockProfit.com announces an investment report featuring Virtual Radiologic Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.
Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shane Taylor Wilkinson, DC 1607 Johnson St., Jennings, LA 70546 Ph: (337) 824-5522 | Dr Shane Taylor Wilkinson, DC 1607 Johnson St., Jennings, LA 70546 Ph: (337) 824-5522 |
News Archive
MicroStockProfit.com announces an investment report featuring Virtual Radiologic Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.
Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.
Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.
CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID) and for the treatment of secondary immunodeficiency (SID). Hizentra is now the first and only 20 percent subcutaneous immunoglobulin (SCIg) therapy in the world for the treatment of these conditions, both of which belong to group of rare and serious diseases of the immune system.
› Verified 1 days ago
Dr. Rhonda Hebert Benoit, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 214 N Church St, Jennings, LA 70546 Phone: 337-248-6166 Fax: 337-824-6169 | |
Chiropractic America,llc Chiropractor Medicare: Medicare Enrolled Practice Location: 1607 Johnson St, Jennings, LA 70546 Phone: 337-824-5522 Fax: 337-824-5527 | |
Dr. David Canon Lister, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 214 N Church St, Jennings, LA 70546 Phone: 337-824-6166 Fax: 337-826-6169 | |
Dr. Kevin Joe Lenderman, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 15375 Highway 26, Jennings, LA 70546 Phone: 337-824-8200 Fax: 337-824-8277 | |
Dr. Joel Harris Conner, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 1322 Elton Rd, Jennings, LA 70546 Phone: 337-329-3352 Fax: 337-824-8892 | |
Charles Joseph Deese, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 217 West Plaquemine St, Jennings, LA 70546 Phone: 337-824-1731 |